Anti-Mitochondrial Antibody Positive Plasma

Anti-Mitochondrial Antibody Positive Plasma Catalog B2010776 (1 mL)

Human plasma enriched with anti-mitochondrial antibodies (AMA), engineered as a consistent and reliable positive control for immunoassay development and mitochondrial autoantibody research. Anti-Mitochondrial Antibody Positive Plasma (Catalog B2010776, 1 mL) serves as an invaluable tool for assay validation, calibration, and method verification in studies involving mitochondrial antigens. Its high-quality formulation ensures consistent antibody presence and reproducibility across batches, supporting a wide range of research workflows including ELISA, western blotting, and flow cytometry.

Clinically relevant and highly characterized, this plasma standard streamlines the development of diagnostics targeting autoimmune mitochondrial disorders, while also supporting basic science research into mitochondrial autoimmune pathways. Delivered as a ready-to-use plasma format, it integrates seamlessly into screening panels, quality control protocols, and reference standards for autoantibody detection. Custom bulk quantities are available to meet the needs of long-term or high-volume studies.

Prepared under strict biotech-grade conditionswith ultrapure water and sterile filtrationand stored at 20 C to maintain antibody integrity, this product is strictly for Research Use Only (RUO) and not intended for clinical or therapeutic purposes.

Why researchers choose this product:

• Validated human plasma positive for anti-mitochondrial antibodies
• Ideal as a control in immunoassays and autoantibody studies
• Ultra-pure biotech-grade preparation ensures experimental consistency
• Convenient 1 mL volume with cold storage for stability
• Custom bulk amounts available for extended or high-throughput workflows

Indication for Use:
This product is for Research Use Only (RUO). It is not intended for diagnostic, therapeutic, or clinical applications.

References:

• 1: Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee H, Koppula P, Wu S, Zhuang L, Fang B, Poyurovsky MV, Olszewski K, Gan B. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer Nature. 2021 May;593(7860):586-590.
• 2: Bauer G. HOCl and the control of oncogenesis J Inorg Biochem. 2018 Feb;179:10-23.
• 3: Morikawa K, Gouttenoire J, Hernandez C, Dao Thi VL, Tran HT, Lange CM, Dill MT, Heim MH, Donz O, Penin F, Quadroni M, Moradpour D. Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease Hepatology. 2014 Feb;59(2):423-33.
• 4: Kielkopf CL, Bauer W, Urbatsch IL. Analysis of Proteins by Immunoblotting Cold Spring Harb Protoc. 2021 Dec 1;2021(12).
• 5: Mohammadyani D, Yanamala N, Samhan-Arias AK, Kapralov AA, Stepanov G, Nuar N, Planas-Iglesias J, Sanghera N, Kagan VE, Klein-Seetharaman J. Structural characterization of cardiolipin-driven activation of cytochrome c into a peroxidase and membrane perturbation Biochim Biophys Acta Biomembr. 2018 May;1860(5):1057-1068.
• 6: Ni D, Xu P, Gallagher S. Immunoblotting and Immunodetection Curr Protoc Protein Sci. 2017 Apr 3;88:10.10.1-10.10.37.
• 7: Di Leone S, Avsar SY, Belluati A, Wehr R, Palivan CG, Meier W. Polymer-Lipid Hybrid Membranes as a Model Platform to Drive Membrane-Cytochrome c Interaction and Peroxidase-like Activity J Phys Chem B. 2020 Jun 4;124(22):4454-4465.
• 8: Behnisch-Cornwell S, Bandaru SSM, Napierkowski M, Wolff L, Zubair M, Urbainsky C, Lillig C, Schulzke C, Bednarski PJ. Pentathiepins: A Novel Class of Glutathione Peroxidase 1 Inhibitors that Induce Oxidative Stress, Loss of Mitochondrial Membrane Potential and Apoptosis in Human Cancer Cells ChemMedChem. 2020 Aug 19;15(16):1515-1528.
• 9: Li M, Sun W, Tyurin VA, DeLucia M, Ahn J, Kagan VE, van der Wel PCA. Activation of Cytochrome C Peroxidase Function Through Coordinated Foldon Loop Dynamics upon Interaction with Anionic Lipids J Mol Biol. 2021 Jul 23;433(15):167057.
• 10: Ni D, Xu P, Gallagher S. Immunoblotting and Immunodetection Curr Protoc Immunol. 2016 Aug 1;114:8.10.1-8.10.36.